151 related articles for article (PubMed ID: 35033435)
1. Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.
Winzenrieth R; Humbert L; Boxberger JI; Weiss RJ; Wang Y; Kostenuik P
J Clin Densitom; 2022; 25(3):392-400. PubMed ID: 35033435
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.
Winzenrieth R; Ominsky MS; Wang Y; Humbert L; Weiss RJ
Osteoporos Int; 2021 Mar; 32(3):575-583. PubMed ID: 33496831
[TBL] [Abstract][Full Text] [Related]
3. Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA).
Winzenrieth R; Kostenuik P; Boxberger J; Wang Y; Humbert L
JBMR Plus; 2022 Apr; 6(4):e10612. PubMed ID: 35434451
[TBL] [Abstract][Full Text] [Related]
4. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
5. The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.
Sone T; Ohnaru K; Sugai T; Yamashita A; Okimoto N; Inoue T; Matsumoto T
Arch Osteoporos; 2023 Nov; 18(1):146. PubMed ID: 38030806
[TBL] [Abstract][Full Text] [Related]
6. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.
Ito M; Oishi R; Fukunaga M; Sone T; Sugimoto T; Shiraki M; Nishizawa Y; Nakamura T
Osteoporos Int; 2014 Mar; 25(3):1163-72. PubMed ID: 24345886
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Chiba K; Okazaki N; Kurogi A; Watanabe T; Mori A; Suzuki N; Adachi K; Era M; Yokota K; Inoue T; Yabe Y; Furukawa K; Kondo C; Tsuda K; Ota S; Isobe Y; Miyazaki S; Morimoto S; Sato S; Nakashima S; Tashiro S; Yonekura A; Tomita M; Osaki M
Bone; 2022 Jul; 160():116416. PubMed ID: 35398293
[TBL] [Abstract][Full Text] [Related]
8. Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
Winzenrieth R; Humbert L; Di Gregorio S; Bonel E; García M; Del Rio L
Osteoporos Int; 2018 Oct; 29(10):2323-2333. PubMed ID: 29974136
[TBL] [Abstract][Full Text] [Related]
9. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
[TBL] [Abstract][Full Text] [Related]
10. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
11. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.
Ito M; Nakamura T; Fukunaga M; Shiraki M; Matsumoto T
Bone; 2011 Sep; 49(3):328-34. PubMed ID: 21605716
[TBL] [Abstract][Full Text] [Related]
12. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
[TBL] [Abstract][Full Text] [Related]
13. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
[TBL] [Abstract][Full Text] [Related]
14. DXA-Based 3D Analysis of the Cortical and Trabecular Bone of Hip Fracture Postmenopausal Women: A Case-Control Study.
Humbert L; Bagué A; Di Gregorio S; Winzenrieth R; Sevillano X; González Ballester MÁ; Del Rio L
J Clin Densitom; 2020; 23(3):403-410. PubMed ID: 30503030
[TBL] [Abstract][Full Text] [Related]
15. Modification of bone mineral density, bone geometry and volumetric BMD in young women with obesity.
Maïmoun L; Renard E; Humbert L; Aouinti S; Mura T; Boudousq V; Lefebvre P; Mahadea K; Philibert P; de Santa-Barbara P; Avignon A; Guillaume S; Sultan A; Nocca D; Mariano-Goulart D
Bone; 2021 Sep; 150():116005. PubMed ID: 33992821
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
Miller PD; Hattersley G; Lau E; Fitzpatrick LA; Harris AG; Williams GC; Hu MY; Riis BJ; Russo L; Christiansen C
Bone; 2019 Mar; 120():137-140. PubMed ID: 30359763
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
Kleerekoper M; Greenspan SL; Lewiecki EM; Miller PD; Kendler DL; Maricic M; Keaveny TM; Kopperdahl DL; Ruff VA; Wan X; Janos B; Krohn K
J Bone Joint Surg Am; 2014 Jun; 96(11):e90. PubMed ID: 24897747
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Bone Impairment by 3D DXA Hip Measures in Patients With Primary Hyperparathyroidism: A Pilot Study.
Gracia-Marco L; García-Fontana B; Ubago-Guisado E; Vlachopoulos D; García-Martín A; Muñoz-Torres M
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31588503
[TBL] [Abstract][Full Text] [Related]
20. Predictive ability of novel volumetric and geometric indices derived from dual-energy X-ray absorptiometric images of the proximal femur for hip fracture compared with conventional areal bone mineral density: the Japanese Population-based Osteoporosis (JPOS) Cohort Study.
Iki M; Winzenrieth R; Tamaki J; Sato Y; Dongmei N; Kajita E; Kouda K; Yura A; Tachiki T; Kamiya K; Kagamimori S
Osteoporos Int; 2021 Nov; 32(11):2289-2299. PubMed ID: 34041560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
